Axon Enterprise Inc vs AstraZeneca plc — how do they compare? Axon Enterprise Inc trades at $600 (market cap $51.69B), while AstraZeneca plc trades at $158.37 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 4.8× Axon Enterprise Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.
| AXON | AZN | |
|---|---|---|
Market Cap | $51.69B | $248.14B |
Sector | Technology | Health |
52-Week High | $791.62 | $209.48 |
52-Week Low | $345.94 | $147.06 |
Enterprise Value | $52.83B | $275.41B |
Dividend Yield | — | 2.01% |
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise trades at $595.63, showing slight consolidation after recent strength with a bullish technical outlook. The company delivered strong Q2 2026 results with 35% revenue growth and raised full-year guidance, though valuation metrics remain elevated with a P/E of 265. Analyst sentiment is overwhelmingly positive with 81% buy ratings and a $685 consensus target.
Axon's razor-and-blade model drives hardware adoption and high-margin software growth, supported by AI capabilities and $15.1B in future contracted bookings. Key risks include valuation concerns, gross margin pressure from service mix, and execution challenges in scaling new products. The stock offers growth exposure but requires monitoring of margin trends.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →